Jiangsu Kanion PharmaceuticalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Jiangsu Kanion PharmaceuticalLtd şirketinin toplam hissedar öz sermayesi CN¥5.3B ve toplam borcu CN¥1.9M olup, bu da borç-öz sermaye oranını 0.04% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥6.9B ve CN¥1.6B dir. Jiangsu Kanion PharmaceuticalLtd 'in FAVÖK'ü CN¥386.5M faiz karşılama oranı -8.6 dur. Şirketin CN¥2.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.04%

Borç/özkaynak oranı

CN¥1.93m

Borç

Faiz karşılama oranı	-8.6x
Nakit	CN¥2.14b
Eşitlik	CN¥5.34b
Toplam yükümlülükler	CN¥1.57b
Toplam varlıklar	CN¥6.90b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

With EPS Growth And More, Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Makes An Interesting Case

Aug 19

Here's Why Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Has Caught The Eye Of Investors

May 21

Shareholders Can Be Confident That Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings Are High Quality

Apr 25

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Mar 04

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Shares Fly 34% But Investors Aren't Buying For Growth

Mar 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 600557 'nin kısa vadeli varlıkları ( CN¥3.7B ) kısa vadeli yükümlülüklerini ( CN¥1.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: 600557 şirketinin kısa vadeli varlıkları ( CN¥3.7B ) uzun vadeli yükümlülüklerini ( CN¥130.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 600557 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 600557 'nin borç/öz sermaye oranı son 5 yılda 18.6% seviyesinden 0.04% seviyesine düştü.

Borç Kapsamı: 600557 'nin borcu işletme nakit akışı ( 45432.4% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 600557 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Jiangsu Kanion PharmaceuticalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Earnings quality

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million.

Investor sentiment improves as stock rises 15%

Price target decreased by 12% to CN¥22.24

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

With EPS Growth And More, Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Makes An Interesting Case

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

Here's Why Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Has Caught The Eye Of Investors

Shareholders Can Be Confident That Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings Are High Quality

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Price target increased by 8.2% to CN¥25.55

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Shares Fly 34% But Investors Aren't Buying For Growth

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Price target decreased to CN¥17.12

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.14 in 2Q 2021)

Price target increased to CN¥21.70

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Price target decreased to CN¥13.10

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

Analysts lower revenue estimates to CN¥4.37b

First half earnings released

Price target raised to CN¥15.45

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

Finansal Durum Analizi